Opus Medical Therapies is developing a transseptal transcatheter mitral valve replacement (TMVR) device leveraging its proprietary anchoring platform. The Opus anchoring platform can be used to secure any intracardiac implant but the company is currently focused on addressing the challenging mitral regurgitation market. The Opus TMVR device treats primary and secondary mitral regurgitation while allowing normal cardiac motion. Opus’ transcatheter heart valve technology is also well suited to treat tricuspid valve regurgitation.